Immunohistochemistry News and Research

RSS

Immunohistochemistry (IHC) is an imaging technique to visualize antigens in cells. Labeled antibodies bind to target antigens in the cell to image the distribution and localization of specific proteins of interest

German researchers find way to accurately differentiate prostate cancer from benign tissue

Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.

6 Feb 2018

CAP releases new guideline for HPV testing in patients with head and neck cancers

Certain head and neck cancers that are positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment.

11 Jan 2018

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Oncologists find new biomarker for breast cancer having poor prognosis

With the support of the FWF, an oncologist found a biomarker for breast cancer having a poor prognosis and developed two viable methods to detect it in tissue samples.

22 Nov 2017

Excess weight linked to higher degree of synovitis in RA patients

Excess weight is linked to a higher degree of synovitis in people with rheumatoid arthritis and can affect their treatment response, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

Novel gene expression signature assay could help enhance lymphoma management

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

17 Oct 2017

Proscia’s new product optimized for digital clinical workflows in anatomic pathology labs

Proscia announced today the launch of a new product optimized for digital clinical workflows in anatomic pathology labs. This new platform is set to transform the clinical use of digital pathology in commercial and hospital labs

30 Sep 2017

EPFL scientists discover metabolic differences between hepatoblastoma subtypes

Hepatoblastoma is a rare pediatric liver cancer, usually diagnosed in the first three years of life. Histological methods are used to distinguish between the different subtypes of hepatoblastoma.

18 Sep 2017

BWH researchers identify new rare genetic cause of peritoneal mesothelioma

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation.

14 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Scientists find simple way to raise accuracy of diagnostic tests and common assays

Scientists at the University of Washington have discovered a simple way to raise the accuracy of diagnostic tests for medicine and common assays for laboratory research.

18 Jul 2017

Two-pronged algorithm may prove to be accurate tool for predicting response to checkpoint inhibitors

The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.

7 Jun 2017

NeoGenomics, Definiens expand alliance to develop novel biomarker assays for clinical trials and testing

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics solutions from biomarker discovery to meaningful diagnostics, today announced that they have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.

20 Mar 2017

Clinical trials – how can patients get the most benefit out of them?

Putting patients at the centre of clinical trial research is perhaps something that goes without saying. At the Clinical Innovation and Partnering World congress in London last week, this was much discussed, along with the need to increase efforts into engaging patients to take part in clinical trials, and the fact that patients are sometimes suspicious of research because it is not explained enough and patient engagement is poor.

16 Mar 2017

Johns Hopkins researchers find no evidence of CMV in aggressive brain cancer tissues

In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say they have found no evidence of cytomegalovirus (CMV) infection and conclude that a link between the two diseases, as claimed by earlier reports, likely does not exist.

1 Mar 2017

HC-based NGS helps detect genomic alterations not identified in routine lung cancer screening

The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.

17 Nov 2016

Immunohistochemistry News and Research

Further Reading